Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.57 |
| ▸ | CCR3 | P51677 | 1/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.52 |
| ▸ | DPP4 | P27487 | 3/20 | 0.51 |
| ▸ | NAMPT | P43490 | 1/20 | 0.51 |
| ▸ | HRH2 | P25021 | 1/20 | 0.49 |
| ▸ | HRH1 | P35367 | 1/20 | 0.49 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.48 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5473968 | 0.90 | SCN9A (0.68) | L3MBTL1SCN9ACCR3HRH3DPP4 | |
| SCHEMBL18502027 | 0.88 | L3MBTL3 (0.66) | L3MBTL3L3MBTL1CCR3HRH3CHRM4 | |
| SCHEMBL18502089 | 0.87 | L3MBTL3 (0.64) | L3MBTL3L3MBTL1HRH3CHRM4DRD3 | |
| SCHEMBL18502043 | 0.87 | L3MBTL1 (0.64) | L3MBTL3L3MBTL1SCN9ACCR3HRH3 | |
| SCHEMBL18502091 | 0.87 | L3MBTL1 (0.64) | L3MBTL3L3MBTL1HRH3CHRM4 | |
| SCHEMBL18502042 | 0.87 | L3MBTL3 (0.64) | L3MBTL3L3MBTL1HRH3DPP4CHRM4 | |
| SCHEMBL18502044 | 0.87 | L3MBTL3 (0.64) | L3MBTL3L3MBTL1HRH3CHRM4DRD3 | |
| SCHEMBL17194188 | 0.87 | L3MBTL3 (0.67) | L3MBTL3L3MBTL1CCR3HRH3CHRM4 | |
| SCHEMBL18507067 | 0.85 | L3MBTL3 (0.62) | L3MBTL3L3MBTL1HRH3DPP4CHRM4 | |
| SCHEMBL18502049 | 0.85 | L3MBTL3 (0.61) | L3MBTL3L3MBTL1CCR3HRH3CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3131890-B1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | PASTEUR INSTITUT KOREA (KR) | 2019-04-24 | — | — | EP | disclosed |
| US-9809602-B2 | Compounds for treating viral infections | INSTITUT PASTEUR KOREA (KR) | 2017-11-07 | — | — | US | disclosed |
| US-20170044181-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | INSTITUT PASTEUR KOREA (KR) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044181-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | HAVCR2, MAVS, EIF2AK2 | L3MBTL3 842/4885L3MBTL1 992/4885SCN9A 4769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.